Oxford Vaccine Again … People could start vaccinating in January

As the epidemic continues to claim more lives and the number of people infected with the coronavirus reaches 50 million, the world awaits the dawn of the vaccine, which will end the multi-month Corona series.

In this context, the CEO of the giant “AstraZeneca” (Anglo-Swedish) pharmaceutical industries has renewed his hope that the vaccine candidate for Corona will be ready for use at the end of December pending regulatory approval.

Vaccination at the end of December ?!

In an interview with Swedish newspaper “Dagenz Nyther”, the company’s chief executive Pascal Suriot said: “Regulators are constantly working with our data, and if it’s quick when we’re ready, we can start. to vaccinate people in January, and maybe at the end of December. “

Regarding the expected benefits of this vaccine if approved, he said: Maybe we will never benefit, no one knows how many times a person will need to be vaccinated because if the vaccine is very effective and people protect for many years, and the disease goes away, then there is no profitable market!

At the same time, however, he indicated that many experts believe that there will be a periodic need for revaccination from time to time, adding: “If it has to be done annually, we can make a profit from 2022” He continued, “But first we have to make sure the vaccine is working effectively.”

Of note, the person responsible for managing the Covid 19 Vaccine Trial Working Group that the University of Oxford is conducting in conjunction with AstraZeneca last week hinted at a very small possibility that the vaccine to be launched before the end of December, indicating that the final results of vaccine trials would initially be released before the end of this year.

This vaccine suffered a setback last month with the death of a Brazilian volunteer during clinical trials, but the British University has confirmed that testing of the vaccine will continue even after the death of the volunteer, who will investigate his situation.

As before, final clinical trials were also temporarily halted at the beginning of last September, after a volunteer fell ill in Britain. AstraZeneca then described the matter as a “routine procedure” that takes place in the event that a participant suffers from an “uncertain illness”, confirming the following. The results of the experiments are being closely monitored around the world.